Novel Alzheimer’s therapies have been given to 19 pct of outpatients who applied for the medications, according to a recent survey at a Tokyo hospital. The lecanemab and donanemab therapies for early-stage Alzheimer’s patients are now clinically available under Japan’s national health insurance scheme, which curbs a sharp rise in out-of-pocket medical expenses. Despite the relatively low-cost availability, however, the drugs have eventually been administered to only 87 out of 456 applicants, the survey by a study group at the Tokyo Metropolitan Institute for Geriatrics and Gerontology showed.